查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1968740

罕见肾臟病市场分析及预测（至2035年）：按类型、产品类型、服务、技术、组件、应用、最终用户、设备、流程和解决方案划分

Rare Kidney Diseases Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, End User, Device, Process, Solutions
出版日期: | 出版商: Global Insight Services | 英文 310 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计罕见肾臟病市场规模将从2024年的34亿美元成长至2034年的155亿美元，复合年增长率约为16.4%。罕见肾臟病市场涵盖低发病率和复杂病理生理机制的罕见肾臟病的诊断、治疗和管理。该市场包括旨在改善患者预后的创新治疗方法、个人化医疗方案和先进诊断工具。公众意识的提高、基因研究的进展以及策略合作正在推动市场成长，而监管激励措施和孤儿药认定则为利益相关人员提供了丰厚的机会。

罕见肾臟病市场正经历显着成长，这主要得益于医学研究的进步和个人化治疗方案的推动。治疗药物领域成长最为迅猛，其中生物製药和基因疗法凭藉其标靶定向和长期疾病管理的潜力，成为成长的主要驱动力。小分子药物紧随其后，其口服给药的便利性和对多种肾病变的广泛适用性提供了互补优势。诊断工具，特别是基因检测和生物标记鑑定，日益重要，反映出人们对早期检测和精准疾病表征的重视程度不断提高。次世代定序技术已成为该领域全面基因分析的关键动力。包括数位健康解决方案和远端医疗平台在内的患者支援服务也在蓬勃发展，有助于提高患者参与度和治疗依从性。人工智慧在预测分析和病患监测的应用进一步增强了市场动态，推动了疾病管理的创新和效率提升。

市场区隔
类型 多囊性肾病变、亚伯氏症候群、法布瑞氏症、肾痨、胱胺酸症、原发性高草酸尿症、肾小管酸中毒、巴特氏症候群、吉特曼症候群
产品 药品、生物製药、基因疗法、诊断试剂、医疗设备、营养补充品、透析机
服务 咨询服务、临床试验、病患援助计画、遗传咨询、远端医疗、检测服务
科技 CRISPR-Cas9、 RNA干扰、次世代定序、生物标记鑑定、3D生物列印、奈米技术
成分 活性药物成分、辅料、给药系统、诊断试剂盒、监测设备
应用领域 治疗、诊断、监测、病患监测、再生医学
最终用户 医院、专科诊所、研究机构、生技公司、製药公司、学术机构
医疗设备 透析机、超音波诊断设备、核磁共振造影系统、基因分析机
过程 药物研发、临床试验、监理核准、生产及分销
解决方案 整合式医疗模式、个人化医疗、数据分析解决方案、病患管理系统

市场概况：

罕见肾臟病市场正经历着动态演变，主要参与者之间的市场份额分布呈现出多样化的特征。定价策略竞争激烈，受到创新和新型治疗方法推出的影响。近期推出的产品，尤其着重于标靶治疗和个人化医疗方法，正在为市场注入新的活力。这些发展正在重塑市场格局，并为成长和投资提供充满希望的途径。适应性定价模式和策略合作伙伴关係对于提高可及性和可负担性至关重要，从而扩大患者覆盖率和市场渗透率。罕见肾臟病市场的竞争日益激烈，主要企业正透过策略性收购和伙伴关係主导。基准分析显示，企业高度重视研发以获得竞争优势。监管具有重要影响，严格的指导方针规范产品开发和市场准入。遵守这些法规对于持续成长和创新至关重要。生物技术的进步和对罕见肾病发病机制的更深入理解有望推动市场扩张。产业相关人员需要巧妙地应对监管环境，才能抓住新的机会。

主要趋势和驱动因素：

罕见肾臟病市场正经历着变革性的成长，这主要得益于基因监测和个人化医疗技术的进步。治疗方法投入的增加，尤其是在基因疗法和精准医疗等领域，是推动市场发展的显着趋势。製药公司正利用最尖端科技，透过开发标靶治疗来提高疗效并最大限度地减少副作用。罕见肾臟病患疾病率的上升以及医疗专业人员对该疾病的认知不断提高，正在推动市场扩张。患者权益倡导组织在提高公众意识和促进早期诊断方面发挥关键作用，进一步推动了对创新治疗方法的需求。监管机构正在简化罕见疾病药物的核准流程，鼓励製药公司投资于此细分市场。此外，生物技术公司与研究机构之间的策略合作正在促进创新并加速开发平臺。数位健康解决方案和远端医疗的兴起正在改善病患管理和获得专科护理的机会。所有这些因素共同作用，为罕见肾臟病市场带来了持续成长和盈利的市场机会。

限制与挑战：

罕见肾臟病市场面临许多显着的限制和挑战。其中一个主要障碍是人们对这些疾病的了解有限，这阻碍了有效治疗方法的研发。知识的匮乏导致研发週期延长，新治疗方法的推出速度也随之放缓。此外，药物研发和临床试验的高成本也是一大障碍。罕见肾臟病通常需要个人化治疗，这加重了製药公司和患者的经济负担。这些治疗的医保覆盖范围仍然不均衡，进一步增加了患者获得治疗的难度。每种罕见肾病的患者群体规模较小也是一个挑战。这限制了潜在市场规模，并阻碍了大型製药公司在该领域的投资。因此，投入此细分领域的研发资源正在减少。此外，监管障碍也增加了复杂性。罕见疾病治疗药物的核准流程通常十分复杂，需要详细的文件和证据。最后，缺乏具备罕见肾臟病专业知识的医疗专业人员也进一步限制了患者照护和治疗进展。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 多囊肾
    • 亚伯氏症候群
    • 法布瑞氏症
    • 肾痨
    • 胱胺酸病
    • 原发性草酸尿症
    • 肾小管酸中毒
    • 巴特氏症候群
    • 吉特曼症候群
  • 市场规模及预测：依产品划分
    • 製药
    • 生物製药
    • 基因治疗
    • 诊断
    • 医疗设备
    • 营养保健品
    • 透析机
  • 市场规模及预测：依服务划分
    • 咨询服务
    • 临床试验
    • 患者援助计划
    • 遗传咨询
    • 远端医疗
    • 检查服务
  • 市场规模及预测：依技术划分
    • CRISPR-Cas9
    • RNA干扰
    • 次世代定序
    • 生物标记鑑定
    • 3D生物列印
    • 奈米科技
  • 市场规模及预测：依组件划分
    • 活性成分
    • 添加剂
    • 配送系统
    • 诊断试剂盒
    • 监控设备
  • 市场规模及预测：依应用领域划分
    • 治疗
    • 诊断
    • 调查
    • 病患监测
    • 再生医学
  • 市场规模及预测：依最终用户划分
    • 医院
    • 专科诊所
    • 研究所
    • 生技公司
    • 製药公司
    • 学术机构
  • 市场规模及预测：依设备划分
    • 透析机
    • 超音波设备
    • 核磁共振造影系统
    • 基因分析设备
  • 市场规模及预测：依製程划分
    • 药物研发
    • 临床试验
    • 监管部门核准
    • 製造业
    • 分配
  • 市场规模及预测：按解决方案划分
    • 整合照顾模式
    • 个人化医疗
    • 数据分析解决方案
    • 病患管理系统

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Otsuka Pharmaceutical
  • Travere Therapeutics
  • ChemoCentryx
  • Calliditas Therapeutics
  • Chinook Therapeutics
  • Reata Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Akebia Therapeutics
  • Vifor Pharma
  • Cara Therapeutics
  • Angion Biomedica
  • Goldfinch Bio
  • Retrophin
  • Dicerna Pharmaceuticals
  • Vertex Pharmaceuticals

第九章：关于我们

简介目录
Product Code: GIS34200

Rare Kidney Diseases Market is anticipated to expand from $3.4 billion in 2024 to $15.5 billion by 2034, growing at a CAGR of approximately 16.4%. The Rare Kidney Diseases Market encompasses the diagnosis, treatment, and management of uncommon renal disorders, characterized by low prevalence and complex pathophysiology. This market includes innovative therapeutics, personalized medicine approaches, and advanced diagnostic tools aimed at improving patient outcomes. Increasing awareness, advancements in genetic research, and strategic collaborations are propelling growth, while regulatory incentives and orphan drug designations offer lucrative opportunities for stakeholders.

The Rare Kidney Diseases Market is experiencing significant growth, fueled by advancements in medical research and personalized treatment approaches. The therapeutics segment is the top performer, with biologics and gene therapies leading the charge due to their targeted efficacy and potential for long-term disease management. Small molecule drugs follow closely, offering complementary benefits with their oral administration and broad applicability across various kidney disorders. Diagnostic tools, particularly genetic testing and biomarker identification, are gaining prominence, reflecting the increasing emphasis on early detection and precise disease characterization. Within this segment, next-generation sequencing technologies are emerging as a critical component, enabling comprehensive genetic profiling. Patient support services, including digital health solutions and telemedicine platforms, are also on the rise, facilitating improved patient engagement and adherence to treatment regimens. The integration of artificial intelligence in predictive analytics and patient monitoring is further enhancing market dynamics, driving innovation and efficiency in disease management.

Market Segmentation
TypePolycystic Kidney Disease, Alport Syndrome, Fabry Disease, Nephronophthisis, Cystinosis, Primary Hyperoxaluria, Renal Tubular Acidosis, Bartter Syndrome, Gitelman Syndrome
ProductPharmaceuticals, Biologics, Gene Therapies, Diagnostics, Medical Devices, Nutraceuticals, Dialysis Equipment
ServicesConsultation Services, Clinical Trials, Patient Support Programs, Genetic Counseling, Telemedicine, Laboratory Services
TechnologyCRISPR-Cas9, RNA Interference, Next-Generation Sequencing, Biomarker Identification, 3D Bioprinting, Nanotechnology
ComponentActive Pharmaceutical Ingredients, Excipients, Delivery Systems, Diagnostic Kits, Monitoring Devices
ApplicationTreatment, Diagnosis, Research, Patient Monitoring, Regenerative Medicine
End UserHospitals, Specialty Clinics, Research Institutes, Biotechnology Companies, Pharmaceutical Companies, Academic Institutions
DeviceDialysis Machines, Ultrasound Devices, MRI Machines, Genetic Analyzers
ProcessDrug Development, Clinical Trials, Regulatory Approval, Manufacturing, Distribution
SolutionsIntegrated Care Models, Personalized Medicine, Data Analytics Solutions, Patient Management Systems

Market Snapshot:

The Rare Kidney Diseases Market is witnessing a dynamic evolution, characterized by diverse market share distribution among key players. Pricing strategies remain competitive, influenced by innovation and the introduction of novel therapies. Recent product launches have invigorated the market, focusing on targeted treatments and personalized medicine approaches. These developments are reshaping the landscape, offering promising avenues for growth and investment. The market's adaptive pricing models and strategic collaborations are pivotal in enhancing accessibility and affordability, thus expanding the patient reach and market penetration. Competition in the Rare Kidney Diseases Market is intensifying, with leading companies vying for dominance through strategic acquisitions and partnerships. Benchmarking reveals a focus on research and development to gain a competitive edge. Regulatory influences are significant, with stringent guidelines shaping product development and market entry. Compliance with these regulations is crucial for sustained growth and innovation. The market is poised for expansion, driven by advancements in biotechnology and an increasing understanding of rare kidney pathologies. Industry players must navigate regulatory landscapes adeptly to capitalize on emerging opportunities.

Geographical Overview:

The rare kidney diseases market is witnessing diverse growth across various regions, each presenting unique opportunities. North America leads the way, buoyed by advanced healthcare infrastructure and significant investment in research and development. The presence of key pharmaceutical companies further accelerates market expansion. Europe follows closely, with strong regulatory frameworks and government support fostering innovation in rare kidney disease treatments. The region's focus on personalized medicine enhances its market potential. In Asia Pacific, the market is expanding rapidly, driven by increasing awareness and rising healthcare expenditure. Emerging economies like China and India are investing heavily in healthcare infrastructure, creating new growth pockets. Latin America and the Middle East & Africa are emerging markets with untapped potential. Latin America shows promise with growing healthcare investments, while the Middle East & Africa are recognizing the importance of addressing rare kidney diseases to improve public health outcomes and drive economic growth.

Key Trends and Drivers:

The Rare Kidney Diseases Market is experiencing transformative growth driven by advancements in genetic research and personalized medicine. Emerging trends include increased investment in R&D for novel therapeutic approaches, focusing on gene therapy and precision medicine. Pharmaceutical companies are leveraging cutting-edge technologies to develop targeted treatments, enhancing efficacy and minimizing side effects. The growing prevalence of rare kidney diseases, coupled with heightened awareness among healthcare professionals, is propelling market expansion. Patient advocacy groups are playing a crucial role in raising awareness and facilitating early diagnosis, further driving demand for innovative treatments. Regulatory bodies are streamlining approval processes for orphan drugs, encouraging pharmaceutical firms to invest in this niche market. Moreover, strategic collaborations between biotech companies and research institutions are fostering innovation and accelerating the development pipeline. The rise of digital health solutions and telemedicine is improving patient management and access to specialized care. These factors collectively position the Rare Kidney Diseases Market for sustained growth and lucrative opportunities.

Restraints and Challenges:

The market for rare kidney diseases is confronted with several notable restraints and challenges. A significant obstacle is the limited understanding of these diseases, which hampers the development of effective treatments. This lack of knowledge results in prolonged research and development timelines, delaying the introduction of new therapies. Additionally, the high cost of drug development and clinical trials presents a formidable barrier. Rare kidney diseases often require personalized treatments, escalating the financial burden on pharmaceutical companies and patients alike. Insurance coverage for such treatments remains inconsistent, further complicating patient access. The small patient population for each rare kidney disease also poses a challenge. This limits the potential market size, deterring investment from major pharmaceutical companies. Consequently, fewer resources are allocated to research and development in this niche sector. Moreover, regulatory hurdles add to the complexity. Navigating the approval process for rare disease treatments is often arduous, requiring exhaustive documentation and evidence. Lastly, the scarcity of specialized healthcare professionals with expertise in rare kidney diseases further restricts patient care and treatment advancement.

Key Players:

Otsuka Pharmaceutical, Travere Therapeutics, ChemoCentryx, Calliditas Therapeutics, Chinook Therapeutics, Reata Pharmaceuticals, Alnylam Pharmaceuticals, Akebia Therapeutics, Vifor Pharma, Cara Therapeutics, Angion Biomedica, Goldfinch Bio, Retrophin, Dicerna Pharmaceuticals, Vertex Pharmaceuticals

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Device
  • 2.9 Key Market Highlights by Process
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Polycystic Kidney Disease
    • 4.1.2 Alport Syndrome
    • 4.1.3 Fabry Disease
    • 4.1.4 Nephronophthisis
    • 4.1.5 Cystinosis
    • 4.1.6 Primary Hyperoxaluria
    • 4.1.7 Renal Tubular Acidosis
    • 4.1.8 Bartter Syndrome
    • 4.1.9 Gitelman Syndrome
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Pharmaceuticals
    • 4.2.2 Biologics
    • 4.2.3 Gene Therapies
    • 4.2.4 Diagnostics
    • 4.2.5 Medical Devices
    • 4.2.6 Nutraceuticals
    • 4.2.7 Dialysis Equipment
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consultation Services
    • 4.3.2 Clinical Trials
    • 4.3.3 Patient Support Programs
    • 4.3.4 Genetic Counseling
    • 4.3.5 Telemedicine
    • 4.3.6 Laboratory Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 CRISPR-Cas9
    • 4.4.2 RNA Interference
    • 4.4.3 Next-Generation Sequencing
    • 4.4.4 Biomarker Identification
    • 4.4.5 3D Bioprinting
    • 4.4.6 Nanotechnology
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Active Pharmaceutical Ingredients
    • 4.5.2 Excipients
    • 4.5.3 Delivery Systems
    • 4.5.4 Diagnostic Kits
    • 4.5.5 Monitoring Devices
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Treatment
    • 4.6.2 Diagnosis
    • 4.6.3 Research
    • 4.6.4 Patient Monitoring
    • 4.6.5 Regenerative Medicine
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Hospitals
    • 4.7.2 Specialty Clinics
    • 4.7.3 Research Institutes
    • 4.7.4 Biotechnology Companies
    • 4.7.5 Pharmaceutical Companies
    • 4.7.6 Academic Institutions
  • 4.8 Market Size & Forecast by Device (2020-2035)
    • 4.8.1 Dialysis Machines
    • 4.8.2 Ultrasound Devices
    • 4.8.3 MRI Machines
    • 4.8.4 Genetic Analyzers
  • 4.9 Market Size & Forecast by Process (2020-2035)
    • 4.9.1 Drug Development
    • 4.9.2 Clinical Trials
    • 4.9.3 Regulatory Approval
    • 4.9.4 Manufacturing
    • 4.9.5 Distribution
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Integrated Care Models
    • 4.10.2 Personalized Medicine
    • 4.10.3 Data Analytics Solutions
    • 4.10.4 Patient Management Systems

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 End User
      • 5.2.1.8 Device
      • 5.2.1.9 Process
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 End User
      • 5.2.2.8 Device
      • 5.2.2.9 Process
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 End User
      • 5.2.3.8 Device
      • 5.2.3.9 Process
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 End User
      • 5.3.1.8 Device
      • 5.3.1.9 Process
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 End User
      • 5.3.2.8 Device
      • 5.3.2.9 Process
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 End User
      • 5.3.3.8 Device
      • 5.3.3.9 Process
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 End User
      • 5.4.1.8 Device
      • 5.4.1.9 Process
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 End User
      • 5.4.2.8 Device
      • 5.4.2.9 Process
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 End User
      • 5.4.3.8 Device
      • 5.4.3.9 Process
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 End User
      • 5.4.4.8 Device
      • 5.4.4.9 Process
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 End User
      • 5.4.5.8 Device
      • 5.4.5.9 Process
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 End User
      • 5.4.6.8 Device
      • 5.4.6.9 Process
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 End User
      • 5.4.7.8 Device
      • 5.4.7.9 Process
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 End User
      • 5.5.1.8 Device
      • 5.5.1.9 Process
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 End User
      • 5.5.2.8 Device
      • 5.5.2.9 Process
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 End User
      • 5.5.3.8 Device
      • 5.5.3.9 Process
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 End User
      • 5.5.4.8 Device
      • 5.5.4.9 Process
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 End User
      • 5.5.5.8 Device
      • 5.5.5.9 Process
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 End User
      • 5.5.6.8 Device
      • 5.5.6.9 Process
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 End User
      • 5.6.1.8 Device
      • 5.6.1.9 Process
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 End User
      • 5.6.2.8 Device
      • 5.6.2.9 Process
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 End User
      • 5.6.3.8 Device
      • 5.6.3.9 Process
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 End User
      • 5.6.4.8 Device
      • 5.6.4.9 Process
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 End User
      • 5.6.5.8 Device
      • 5.6.5.9 Process
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Otsuka Pharmaceutical
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Travere Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 ChemoCentryx
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Calliditas Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Chinook Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Reata Pharmaceuticals
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Alnylam Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Akebia Therapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Vifor Pharma
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Cara Therapeutics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Angion Biomedica
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Goldfinch Bio
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Retrophin
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Dicerna Pharmaceuticals
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Vertex Pharmaceuticals
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us